Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.



home / news releases / AUPH - Aurinia Pharmaceuticals Is A Long-Term Buy With Near-Term Catalysts


AUPH - Aurinia Pharmaceuticals Is A Long-Term Buy With Near-Term Catalysts

This article was highlighted for PRO subscribers, Seeking Alpha’s service for professional investors. Find out how you can get the best content on Seeking Alpha here.

Aurinia Pharmaceuticals (AUPH) is a Canadian drug company which has recently received expedited FDA review for its lupus nephritis ("LN") treatment Voclosporin. The company announced the details on July 21, 2020 (with my emphasis):

On July 21, 2020, the Company announced that the FDA has accepted the filing of its NDA for voclosporin, as a potential treatment for LN, a serious inflammation of the kidneys caused

Read more ...

Stock Information

Company Name: Aurinia Pharmaceuticals Inc
Stock Symbol: AUPH
Market: NASDAQ
Website: auriniapharma.com

Menu

AUPH AUPH Quote AUPH Short AUPH News AUPH Articles AUPH Message Board
Get AUPH Alerts

News, Short Squeeze, Breakout and More Instantly...